CSIMarket
 
Vericel Corporation  (VCEL)
Other Ticker:  
 
 
Price: $44.2600 $0.05 0.113%
Day's High: $44.94 Week Perf: -0.74 %
Day's Low: $ 43.98 30 Day Perf: -6.94 %
Volume (M): 1,162 52 Wk High: $ 50.09
Volume (M$): $ 51,421 52 Wk Avg: $35.79
Open: $43.98 52 Wk Low: $28.02



 Market Capitalization (Millions $) 2,012
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) 198
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 28

Vericel Corporation
Vericel Corporation is a publicly traded biopharmaceutical company that focuses on developing and commercializing cell therapy products that repair or regenerate human tissue.
The company is headquartered in Cambridge, Massachusetts, and has facilities in Michigan and California.
Vericel's flagship product is called MACI, which stands for Matrix-Induced Autologous Chondrocyte Implantation.
This is a regenerative medicine treatment for patients with knee cartilage damage or disorders.
MACI involves harvesting a patient's own healthy cartilage cells, multiplying them in a laboratory, and then implanting them into the affected area of the knee.
MACI received FDA approval in 2016 and has since been used in thousands of patients.
In addition to MACI, Vericel also sells Epicel, which is a cell-based therapy for treating severe burns.
Epicel involves taking a small sample of a patient's own healthy skin cells, multiplying them in a laboratory, and then grafting them onto the burn wound.
Epicel has been used in over 1,000 patients and is the only FDA-approved cell therapy for the treatment of severe burns.
Vericel has a robust research and development pipeline focused on cell therapy products that target cardiac, pulmonary, and neurological diseases.
The company is committed to advancing science and technology to bring innovative treatments to patients suffering from debilitating conditions.
Overall, Vericel Corporation is a leading player in the field of regenerative medicine, with a focus on developing cell-based therapies that improve patients' quality of life.


   Company Address: 64 Sidney Street Cambridge 2139 MA
   Company Phone Number: 588-5555   Stock Exchange / Ticker: NASDAQ VCEL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vericel Corporation

Vericel Corporation Witnesses Remarkable Deficit Decline during July-Sept 2023, Poised for Steady Growth

In the ever-evolving world of the stock market, there are always companies that stand out with their exceptional performance and potential for growth. Vericel Corporation (NASDAQ:VCEL) is one such company that has captured the attention and admiration of investors.
Vericel Corporation, renowned for its advanced therapies in the sports medicine and severe burn care markets, has recently reported some impressive financial results for the July to September 2023 period. The company's loss per share decreased from $-0.14 to $-0.08 compared to the same period a year ago, showcasing a significant improvement. Furthermore, earnings per share also experienced a notable increase from $-0.11 in the previous financial reporting period.

Vericel Corporation

Vericel Corporation Shatters Expectations With Spectacular 24% Revenue Boost in the 2nd Quarter of 2023

Vericel Corporation, a leading Biotechnology & Pharmaceuticals company, has recently released its financial results for the fiscal interval closing June 30, 2023. The report shows positive progress in terms of earnings per share, revenue, and net shortfall.
Firstly, Vericel Corporation has shown a significant improvement in its loss per share, decreasing it to $-0.11 per share compared to $-0.19 in the previous year. This indicates better financial performance and highlights the company's ability to manage its expenses effectively.

Vericel Corporation

Vericel Corporation Shows Impressive Revenue Growth in Q1 2023, Yet Profits Remain Elusive

Vericel Corporation, a renowned biotechnology and pharmaceutical company, has reported a significant increase in revenue for the financial time-frame ending March 31, 2023. According to the company's financial statements, the revenue increased by 13.702% from the same quarter a year prior to $41.02 million. However, the company recorded a shortfall per share at $-0.16 shortfall per share, which is a cause of concern for the investors.
Interestingly, Vericel Corporation's customers continue to flock to the company, attributing its agile campaign tactics, which focus on attracting clients seeking certainty and value. The company's financial statements show that revenue in the previous quarter fell by -22.16% from $52.69 million. Additionally, the earnings per share (EPS) slid from $0.12 per share, indicating a drop in the company's profits.






 

Vericel's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com